{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T04:31:25Z","timestamp":1768710685830,"version":"3.49.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1124\/dmd.121.000423","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T22:25:17Z","timestamp":1620858317000},"page":"479-489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Multiple Computational Approaches for Predicting Drug Interactions with Human Equilibrative Nucleoside Transporter 1"],"prefix":"10.1016","volume":"49","author":[{"given":"Siennah R.","family":"Miller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberley M.","family":"Zorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Ekins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen H.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan J.","family":"Cherrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.121.000423_bib1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1124\/jpet.112.191577","article-title":"Molecular determinants of ligand selectivity for the human multidrug and toxin extruder proteins MATE1 and MATE2-K","volume":"341","author":"Astorga","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.121.000423_bib2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1139\/y92-005","article-title":"Sodium-dependent nucleoside transport in mouse lymphocytes, human monocytes, and hamster macrophages and peritoneal exudate cells","volume":"70","author":"Baer","year":"1992","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1124\/dmd.121.000423_bib3","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00424-003-1103-2","article-title":"The equilibrative nucleoside transporter family, SLC29","volume":"447","author":"Baldwin","year":"2004","journal-title":"Pflugers Arch"},{"key":"10.1124\/dmd.121.000423_bib4","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0028-3908(97)00136-6","article-title":"Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cells","volume":"36","author":"Boleti","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1124\/dmd.121.000423_bib5","doi-asserted-by":"crossref","first-page":"H3325","DOI":"10.1152\/ajpheart.01006.2007","article-title":"Nucleoside and nucleobase transporters of primary human cardiac microvascular endothelial cells: characterization of a novel nucleobase transporter","volume":"293","author":"Bone","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1124\/dmd.121.000423_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/15257770.2016.1210805","article-title":"Equilibrative nucleoside transporters-A review","volume":"36","author":"Boswell-Casteel","year":"2017","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1124\/dmd.121.000423_bib7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ejps.2005.09.013","article-title":"Computational approaches to modeling drug transporters","volume":"27","author":"Chang","year":"2006","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.121.000423_bib8","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1021\/acs.chemrestox.5b00511","article-title":"Involvement of drug transporters in organ toxicity: the fundamental basis of drug discovery and development","volume":"29","author":"Cheng","year":"2016","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.121.000423_bib9","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1007\/s12272-014-0437-y","article-title":"Contribution of CNT1 and ENT1 to ribavirin uptake in human hepatocytes","volume":"38","author":"Choi","year":"2015","journal-title":"Arch Pharm Res"},{"key":"10.1124\/dmd.121.000423_bib10","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1124\/dmd.115.064956","article-title":"Making transporter models for drug-drug interaction prediction mobile","volume":"43","author":"Ekins","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000423_bib11","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0026-895X(24)12192-X","article-title":"Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates","volume":"61","author":"Ekins","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.121.000423_bib12","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/clpt.2012.164","article-title":"Computational modeling to accelerate the identification of substrates and inhibitors for transporters that affect drug disposition","volume":"92","author":"Ekins","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000423_bib13","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41563-019-0338-z","article-title":"Exploiting machine learning for end-to-end drug discovery and development","volume":"18","author":"Ekins","year":"2019","journal-title":"Nat Mater"},{"key":"10.1124\/dmd.121.000423_bib14","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.bcp.2011.12.042","article-title":"ABC transporters and their role in nucleoside and nucleotide drug resistance","volume":"83","author":"Fukuda","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.121.000423_bib15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0304-4157(96)00008-1","article-title":"Nucleoside and nucleobase transport systems of mammalian cells","volume":"1286","author":"Griffith","year":"1996","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/dmd.121.000423_bib16","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/bdd.2131","article-title":"Contribution of equilibrative nucleoside transporters 1 and 2 to gemcitabine uptake in pancreatic cancer cells","volume":"39","author":"Hioki","year":"2018","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.121.000423_bib17","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1124\/mol.113.086801","article-title":"The role of human equilibrative nucleoside transporter 1 on the cellular transport of the DNA methyltransferase inhibitors 5-azacytidine and CP-4200 in human leukemia cells","volume":"84","author":"Hummel-Eisenbeiss","year":"2013","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.121.000423_bib18","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1248\/bpb.32.741","article-title":"Membrane transport mechanisms of mizoribine in the rat intestine and human epithelial LS180 cells","volume":"32","author":"Ishida","year":"2009","journal-title":"Biol Pharm Bull"},{"key":"10.1124\/dmd.121.000423_bib19","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/978-1-4939-9420-5_26","article-title":"In silico approaches to predict drug-transporter interaction profiles: data mining, model generation, and link to cholestasis","volume":"1981","author":"Jain","year":"2019","journal-title":"Methods Mol Biol"},{"key":"10.1124\/dmd.121.000423_bib20","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1248\/bpb.32.450","article-title":"Characterization of nucleobase transport by mouse Sertoli cell line TM4","volume":"32","author":"Kato","year":"2009","journal-title":"Biol Pharm Bull"},{"key":"10.1124\/dmd.121.000423_bib21","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1124\/mol.105.015768","article-title":"A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems","volume":"69","author":"King","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.121.000423_bib22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1124\/jpet.113.203265","article-title":"Basolateral uptake of nucleosides by Sertoli cells is mediated primarily by equilibrative nucleoside transporter 1","volume":"346","author":"Klein","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.121.000423_bib23","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1124\/dmd.112.049858","article-title":"Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1","volume":"41","author":"Lepist","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000423_bib24","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrd4626","article-title":"SLC transporters as therapeutic targets: emerging opportunities","volume":"14","author":"Lin","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.121.000423_bib25","first-page":"4349","article-title":"Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines","volume":"58","author":"Mackey","year":"1998","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.121.000423_bib26","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1093\/jnci\/91.21.1876","article-title":"Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters","volume":"91","author":"Mackey","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1124\/dmd.121.000423_bib27","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1124\/mol.116.105056","article-title":"Lack of influence of substrate on ligand interaction with the human multidrug and toxin extruder, MATE1","volume":"90","author":"Mart\u00ednez-Guerrero","year":"2016","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.121.000423_bib28","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1124\/dmd.120.090720","article-title":"Nucleoside reverse transcriptase inhibitor interaction with human equilibrative nucleoside transporters 1 and 2","volume":"48","author":"Miller","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000423_bib29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1124\/molpharm.120.000169","article-title":"Predicting drug interactions with human equilibrative nucleoside transporters 1 and 2 using functional knockout cell lines and bayesian modeling","volume":"99","author":"Miller","year":"2021","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.121.000423_bib30","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2174\/157016109789043892","article-title":"Nucleoside transporter proteins","volume":"7","author":"Molina-Arcas","year":"2009","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1124\/dmd.121.000423_bib31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.tips.2010.11.007","article-title":"Emerging role for drug transporters at the blood-testis barrier","volume":"32","author":"Mruk","year":"2011","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/dmd.121.000423_bib32","doi-asserted-by":"crossref","unstructured":"Pastor-Anglada M, Casado FJ (2006) Nucleoside transport into cells, in: Cancer Drug Discovery and Development: Deoxynucleoside Analogs in Cancer Therapy, pp 1\u201328, Humana Press.","DOI":"10.1007\/978-1-59745-148-2_1"},{"key":"10.1124\/dmd.121.000423_bib33","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3389\/fphar.2018.00606","article-title":"Emerging roles of nucleoside transporters","volume":"9","author":"Pastor-Anglada","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1124\/dmd.121.000423_bib34","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1006\/bbrc.2000.4205","article-title":"Differential expression of human nucleoside transporters in normal and tumor tissue","volume":"280","author":"Pennycooke","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/dmd.121.000423_bib35","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/0304-4157(88)90002-0","article-title":"Nucleoside and nucleobase transport in animal cells","volume":"947","author":"Plagemann","year":"1988","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/dmd.121.000423_bib36","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1097\/QAD.0b013e328353b11b","article-title":"Highly active antiretroviral therapy does not completely suppress HIV in semen of sexually active HIV-infected men who have sex with men","volume":"26","author":"Politch","year":"2012","journal-title":"AIDS"},{"key":"10.1124\/dmd.121.000423_bib37","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.bcp.2015.09.019","article-title":"Thermodynamics and kinetics of inhibitor binding to human equilibrative nucleoside transporter subtype-1","volume":"98","author":"Rehan","year":"2015","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.121.000423_bib38","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1177\/2472555219870123","article-title":"Current progress on equilibrative nucleoside transporter function and inhibitor design","volume":"24","author":"Rehan","year":"2019","journal-title":"SLAS Discov"},{"key":"10.1124\/dmd.121.000423_bib39","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1124\/mol.117.111443","article-title":"Assessment of substrate-dependent ligand interactions at the organic cation transporter OCT2 using six model substrates","volume":"94","author":"Sandoval","year":"2018","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.121.000423_bib40","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1002\/jps.24498","article-title":"Saturable hepatic extraction of gemcitabine involves biphasic uptake mediated by nucleoside transporters equilibrative nucleoside transporter 1 and 2","volume":"104","author":"Shimada","year":"2015","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.121.000423_bib41","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/bdd.2110","article-title":"Contribution of equilibrative nucleoside transporter(s) to intestinal basolateral and apical transports of anticancer trifluridine","volume":"39","author":"Takahashi","year":"2018","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.121.000423_bib42","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1248\/bpb.b14-00622","article-title":"Cellular uptake of decitabine by equilibrative nucleoside transporters in HCT116 cells","volume":"38","author":"Ueda","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"10.1124\/dmd.121.000423_bib43","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.dmpk.2019.10.002","article-title":"Numerical analysis of apparent decitabine uptake in HCT116 cells: incorporation of a bidirectional first-order kinetic parameter for ENT1 transport and Michaelis-Menten parameters for subsequent phosphorylation","volume":"35","author":"Ueda","year":"2020","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.121.000423_bib44","doi-asserted-by":"crossref","first-page":"113747","DOI":"10.1016\/j.bcp.2019.113747","article-title":"Affinity, binding kinetics and functional characterization of draflazine analogues for human equilibrative nucleoside transporter 1 (SLC29A1)","volume":"172","author":"Vlachodimou","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.121.000423_bib45","doi-asserted-by":"crossref","first-page":"8375","DOI":"10.1074\/jbc.275.12.8375","volume":"275","author":"Ward","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.121.000423_bib46","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1172\/JCI112823","article-title":"Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells","volume":"79","author":"White","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1124\/dmd.121.000423_bib47","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/0277-5379(83)90029-9","article-title":"Cytosine arabinoside transport by human leukaemic cells","volume":"19","author":"Wiley","year":"1983","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1124\/dmd.121.000423_bib48","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41594-019-0245-7","article-title":"Structures of human ENT1 in complex with adenosine reuptake inhibitors","volume":"26","author":"Wright","year":"2019","journal-title":"Nat Struct Mol Biol"},{"key":"10.1124\/dmd.121.000423_bib49","doi-asserted-by":"crossref","first-page":"32552","DOI":"10.1074\/jbc.M111.236117","article-title":"Nucleobase transport by human equilibrative nucleoside transporter 1 (hENT1)","volume":"286","author":"Yao","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.121.000423_bib50","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.mam.2012.05.007","article-title":"The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29","volume":"34","author":"Young","year":"2013","journal-title":"Mol Aspects Med"},{"key":"10.1124\/dmd.121.000423_bib51","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1080\/00498250801927427","article-title":"Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins","volume":"38","author":"Young","year":"2008","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.121.000423_bib52","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1039\/C6MD00207B","article-title":"From linked open data to molecular interaction: studying selectivity trends for ligands of the human serotonin and dopamine transporter","volume":"7","author":"Zdrazil","year":"2016","journal-title":"MedChemComm"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624077158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624077158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.121.000423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:18:47Z","timestamp":1739956727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624077158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0090955624077158"],"URL":"https:\/\/doi.org\/10.1124\/dmd.121.000423","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple Computational Approaches for Predicting Drug Interactions with Human Equilibrative Nucleoside Transporter 1","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.121.000423","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}